Browsing Category
Featured Articles
Merz and Teijin Announce Partnership to Bring Xeomin (incobotulinumtoxinA) to Japan
Merz and Teijin Limited announced that they have entered into a strategic license and co-development agreement for the commercialization of Xeomin (incobotulinumtoxinA) for Japan.…
Read More...
Read More...
MilliporeSigma Opens New Life Science Center in Massachusetts
MilliporeSigma today officially opened its new Life Science Center in Burlington, Massachusetts. The new center serves as a regional hub for scientific advancement and customer…
Read More...
Read More...
Moffitt Researchers Discover New Targets for Approved Cancer Drug
Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative…
Read More...
Read More...
AbbVie & Turnstone announces collaboration on Viral Immunotherapies in Oncology
AbbVie announced a research, option and license agreement whereby AbbVie obtained an exclusive option to license up to three of Turnstone's next-generation oncolytic viral…
Read More...
Read More...
Astellas Pharma and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin
Astellas Pharma and Seattle Genetics announced dosing of the first patient in EV-201, a registrational phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or…
Read More...
Read More...
FDA grants Priority Review to Gilotrif for uncommon EGFR mutations in advanced NSCLC
Boehringer Ingelheim announced that the supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) has been accepted for filing and granted Priority Review by the U.S. Food and…
Read More...
Read More...
EMA accepts Marketing application for Imfinzi to treat NSCLC patients
AstraZeneca, along with MedImmune, its global biologics research and development arm, has announced that the European Medicines Agency (EMA) has accepted a Marketing…
Read More...
Read More...
Merck Discontinues MK-3682B and MK-3682C Development Programs
Merck announced its strategic decision to discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir) and MK-3682C…
Read More...
Read More...
Pfizer Launches Novel Programs to Put Important Support Services at the Fingertips of Cancer…
Pfizer unveils enhanced offerings to help patients manage their life with cancer. Pfizer Oncology Together is a first-of-its-kind program for patients taking Pfizer Oncology medicines…
Read More...
Read More...
FDA Grants Orphan Drug Designation to Kadmon’s KD025 for the Treatment of cGVHD
Kadmon Holdings announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KD025, the Company’s Rho-associated coiled-coil kinase (ROCK)…
Read More...
Read More...
Smithers Avanza Toxicology Services Adds Peter Capozziello as Director, Business Development
Smithers Avanza, a boutique contract research organization (CRO) supporting the pharmaceutical and chemical industries, named Peter Capozziello its new Director, Business Development.…
Read More...
Read More...
Avara Pharmaceutical sign agreement to acquire Reims from AstraZeneca in France
Avara Pharmaceutical Services has signed and closed on an agreement with AstraZeneca to acquire the Reims, France manufacturing and distribution facility. "This key acquisition is…
Read More...
Read More...
